A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion

European Journal of Cancer

Volumn 45, Issue 14, 2009, Pages 2519-2527

  van Riel, J M ^a   Peters, G J ^a   Mammatas, L H ^a   Honeywell, R J ^a   Laan, A C ^a   Ruyter, R ^a   van den Berg, F G ^a   Giaccone, G ^a   van Groeningen, C J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Gemcitabine; Hepatic arterial chemotherapy; Pharmacokinetics; Phase I study

Indexed keywords

2',2 DIFLUORO 2' DEOXYURIDINE; DRUG METABOLITE; GEMCITABINE; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKOPENIA; LIVER CANCER; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; FEMALE; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; LIVER NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 69249116653     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.05.025     Document Type: Article

References (34)

1. Chen H.S., and Gross J.F. Intra-arterial infusion of anticancer drugs: theoretic aspects of drug delivery and review of responses. Cancer Treat Rep 64 (1980) 31-40
2. Collins J.M. Pharmacologic rationale for regional drug delivery. J Clin Oncol 2 (1984) 498-504
3. Ensminger W.D., and Gyves J.W. Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol 10 (1983) 176-182
4. Breedis C., and Young G. The blood supply of neoplasms in the liver. Am J Pathol 30 (1954) 969-977
5. Cohen A.D., and Kemeny N.E. An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist 8 (2003) 553-566
6. Mocellin S., Pilati P., Lise M., et al. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era?. J Clin Oncol 25 (2007) 5649-5654
7. Burris III H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 (1997) 2403-2413
8. Spielmann M., Llombart Cussac A., Kalla S., et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 60 (2001) 303-307
9. Lorusso V., Pollera C.F., Pollera M., et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 34 (1998) 1208-1212
10. Anderson H., Hopwood P., Stephens R.J., et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer: a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Brit J Cancer 83 (2000) 447-453
11. Plunkett W., Huang P., Searcy C.E., et al. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 23 Suppl 10 (1996) 3-15
12. Kroep J.R., Loves W.J., van der Wilt C.L., et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 1 (2002) 371-376
13. Spasokoukotskaja T., Arner E.S., Brosjo O., et al. Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues. Eur J Cancer 31A (1995) 202-208
14. van der Wilt C.L., Kroep J.R., Loves W.J., et al. Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cell lines, liver metastases and normal liver. Eur J Cancer 39 (2003) 691-697
15. Camiener G.W., and Smith C.G. Studies of the enzymatic deamination of cytosine arabinoside-I. Enzyme distribution and species specificity. Biochem Pharmacol 14 (1965) 1405-1416
16. Zicha B., and Buric L. Deoxycytidine and radiation response: exceedingly high deoxycytidine aminohydrolase activity in human liver. Science 163 (1969) 191-192
17. Vogl T.J., Schwarz W., Eichler K., et al. Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy. J Cancer Res Clin Oncol 132 (2006) 745-755
18. Tse AN, Wu N, Patel D, Haviland D, Kemeny N. A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies. Cancer Chemother Pharmacol 2009. doi:10.1007/s00280-009-045-5.
19. Braakhuis B.J., Ruiz van Haperen V.W., Boven E., et al. Schedule-dependent antitumor effect of gemcitabine in in vivo model system. Semin Oncol 22 Suppl 11 (1995) 42-46
20. Veerman G., Ruiz van Haperen V.W., Vermorken J.B., et al. Antitumor activity of prolonged as compared with bolus administration of 2′,2′-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol 38 (1996) 335-342
21. Anderson H., Thatcher N., Walling J., et al. A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. Brit J Cancer 74 (1996) 460-462
22. Eckel F., Lersch C., Assmann G., et al. Toxicity of a 24-h infusion of gemcitabine in biliary tract and pancreatic cancer: a pilot study. Cancer Invest 20 (2002) 180-185
23. Eckel F., Schmelz R., Erdmann J., et al. Phase II trial of a 24-h infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma. Cancer Invest 21 (2003) 690-694
24. von Delius S., Lersch C., Schulte-Frohlinde E., et al. Phase II trial of weekly 24-h infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. BMC Cancer 5 (2005) 61
25. World Health Organization. Handbook for reporting results of cancer treatment (1979), World Health Organization, Geneva, Switzerland
26. National Cancer Institute. Guidelines for the reporting of adverse drug reactions (1988), Division of Cancer Treatment, National Cancer Institute, Bethesda, MD
27. Honeywell R., Laan A.C., van Groeningen C.J., et al. The determination of gemcitabine and 2′-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry. J Chromatogr B 847 (2007) 142-152
28. Kroep J.R., Giaccone G., Voorn D.A., et al. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol 17 (1999) 2190-2197
29. Collins J.M., Dedrick R.L., King F.G., et al. Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes. Clin Pharmacol Ther 28 (1980) 235-246
30. Mackey J.R., Yao S.Y., Smith K.M., et al. Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst 91 (1999) 1876-1881
31. Ensminger W.D., Rosowsky A., Raso V., et al. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Res 38 (1978) 3784-3792
32. Fety R., Lucas C., Solere P., et al. Hepatic intra-arterial infusion of fotemustine: pharmacokinetics. Cancer Chemother Pharmacol 31 (1992) 118-122
33. Garnick M.B., Ensminger W.D., Israel M., et al. A clinical-pharmacological evaluation of hepatic arterial infusion of adriamycin. Cancer Res 39 (1979) 4105-4110
34. Campbell T.N., Howell S.B., Pfeifle C.E., et al. Clinical pharmacokinetics of intraarterial cisplatin in humans. J Clin Oncol 1 (1983) 755-762